Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.59 | N/A | -2.97% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.59 | N/A | -2.97% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach due to ongoing uncertainties. They emphasized their commitment to advancing their clinical programs.
Management did not provide specific revenue figures for the quarter.
The company is focusing on its ongoing clinical trials and research.
Protagonist Therapeutics reported a loss per share that was slightly worse than expected, contributing to a modest decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's financial outlook. The stock's reaction indicates a cautious sentiment as the company continues to navigate its clinical development efforts.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARATHON PETE CORP
Aug 3, 2020